Key facts
- PanTher Therapeutics’s last known valuation is $10.9M (Jun 2022).
- It has raised $15.5M across 2 recorded rounds; the latest was Seed Round ($3.0M) in Mar 2025.
- Notable investors include MassChallenge, MedTech Innovator, Springboard Enterprises, Keiretsu Forum, Johnson & Johnson Innovation - JLABS — 18 tracked in total.
- PanTher Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Apr 2025 ($3.0M sold to 26 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for PanTher Therapeutics
Funding rounds
2 roundsAbout PanTher Therapeutics
Developer of a cancer treatment technology designed to deliver therapeutics directly to the tumor site. The company's technology allows oncologists to treat patients with cancer by improving a drug's full potential through direct, sustained treatment, enabling medical professionals to provide targeted, effective treatments and improve clinical outcomes.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2014
- Employees
- 10
- Website
- panthertx.com/
- Ownership
- Privately Held (backing)
PanTher Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PanTher Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PanTher Therapeutics in its N-PORT filings yet. We sweep new filings monthly.